12:00 AM
May 17, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CD40 Ligand: Began Phase II testing

(Clinical results, B10)

Immunex Corp. (IMNX), Seattle, Wash.
Product: CD40 Ligand
Business: Cancer
Therapeutic category:...

Read the full 66 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >